Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
C. Aschele(Ospedale San Carlo), Luca Boni, Gerardo Rosati(Ospedale San Carlo), Stefano Cordio(Ospedale San Carlo), Germana Chiaulon(Ospedale San Carlo), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Maurizio Gallo(Ospedale San Carlo), Sara Lonardi(Istituto Oncologico Veneto), Giovanni Ambrosini(Ospedale San Carlo), Domenico Corsi(Ospedale San Carlo), A. Tagliagambe(Ospedale San Carlo), L. Cionini(Ospedale San Carlo), Anna Maria Bochicchio(Ospedale San Carlo), Maria Chiara Tronconi(Ospedale San Carlo), Giovanni Silvano(Ospedale San Carlo), Gabriele Luppi(University of Modena and Reggio Emilia), Andrea Bonetti(Italian Oncology Group of Clinical Research), Salvatore Artale(Ospedale San Carlo), Maria Emanuela Negru(Ospedale San Carlo), Paola Rosetti(Ospedale San Carlo)
Cited by 763
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k